About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
Not Voodoo

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
Realizations in Biostatistics
ChemSpider Blog
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Eye on FDA
Chemical Forums
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa

Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
Gene Expression (I)
Gene Expression (II)
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net

Medical Blogs
DB's Medical Rants
Science-Based Medicine
Respectful Insolence
Diabetes Mine

Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem

Politics / Current Events
Virginia Postrel
Belmont Club
Mickey Kaus

Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« ACS Med Chem Letters | Main | Dundee's NMT Inhibitors for Sleeping Sickness: An Update »

April 9, 2010

Patent Chart Update

Email This Entry

Posted by Derek

I had some correspondence with the people at MassHighTech about their "New England Patent Rankings" chart (which I spoke about here). That's the one that shows Pfizer with only three patents in 2009, which didn't make a whole lot of sense, considering the size of the operation in Groton/New London.

A look through the patent databases (which several readers also confirmed) showed that something was apparently off, since there were numerous Pfizer patents where the inventors all were from Connecticut. But as it turns out, the MassHighTech people say that their consultant looks at the states of the assignees, and filters out any that don't contain CT, VT, ME, NH, MA, or RI. So that means that many Pfizer patents, which are assigned to the company at its global HQ in New York, don't make the cut.

That seems like an odd way to do things, but maybe it's just me. The people at MassHighTech say that they're looking specifically for "New England-based companies" on their list, but in that case, you wonder how even three Pfizer patents made it in.

Comments (5) + TrackBacks (0) | Category: Patents and IP


1. OrgMed on April 9, 2010 9:33 AM writes...

Its interesting that I do not see AZ and Merck.

Permalink to Comment

2. Greg Hlatky on April 9, 2010 10:16 AM writes...

It took me just a couple of minutes to go to the USPTO database and look up Pfizer as an assignee and CT, VT, ME, NH, MA, or RI as inventor states. I got 42 issued patents in 2009. Someone can't (a) read and/or (b) count.

Permalink to Comment

3. Anonymous on April 9, 2010 11:40 AM writes...

Greg - it would appear it is you who cannot read as DL plainly states that the survey was based on the state affiliation of the assignee, not the inventor

Permalink to Comment

4. Anon on April 9, 2010 1:21 PM writes...

This was obviously done with some limited perspective and bias. So what does it matter?

Give it up.

Permalink to Comment

5. Anonymous BMS Researcher on April 10, 2010 2:01 PM writes...

In the case of BMS, our three main R&D sites (two in NJ and one in CT) are very closely integrated; much of my own work involves collaborations among folks in both States. So it would be extremely difficult to devise an accurate way to distinguish "New England" from "non-New England" patents from BMS.

Permalink to Comment


Remember Me?


Email this entry to:

Your email address:

Message (optional):

The Last Post
The GSK Layoffs Continue, By Proxy
The Move is Nigh
Another Alzheimer's IPO
Cutbacks at C&E News
Sanofi Pays to Get Back Into Oncology
An Irresponsible Statement About Curing Cancer
Oliver Sacks on Turning Back to Chemistry